Bristol Myers Squibb: A High Dividend Investment Opportunity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 01 2026
0mins
Should l Buy BMY?
Source: Yahoo Finance
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite the fierce competition and high costs of drug development in the pharmaceutical industry, Bristol Myers Squibb's focus on cardiovascular, cancer, and immune-related medicines presents significant market opportunities, especially as GLP-1 weight-loss drugs capture investor attention.
- Stock Price Pullback and Recovery Potential: The company's stock is approximately 25% below its late 2022 highs, providing investors with an opportunity to benefit from potential price recovery while enjoying a high dividend yield, with a payout ratio of 70% that is not overly concerning.
- Patent Expiration and Development Outlook: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is exploring alternative delivery methods to extend patent protections, and its development pipeline includes other drugs, demonstrating its capability to manage patent expirations effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 59.710
Low
37.00
Averages
55.86
High
68.00
Current: 59.710
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Readystate Asset Management Significantly Reduces Workiva Holdings
- Significant Reduction: Readystate Asset Management sold 361,224 shares of Workiva in Q4 2025, with an estimated transaction value of $31.98 million, reflecting the fund's strategic response to market volatility.
- Decline in Position Value: The quarter-end value of Workiva holdings decreased by $31.09 million, indicating a dual impact from both stock price fluctuations and the share sale, suggesting a potential decline in market confidence towards the company.
- Change in Holdings Proportion: Post-sale, Readystate holds only 10,000 shares of Workiva valued at $862,500, which constitutes 0.03% of its AUM, thus removing Workiva from the fund's top five holdings, highlighting a significant shift in investment strategy.
- Uncertain Market Outlook: Although Workiva's price-to-sales ratio has fallen below 4, indicating potential valuation attractiveness, the impact of AI models on SaaS business models raises uncertainties about future investment returns, necessitating cautious evaluation by investors.
See More
Readystate Asset Management Sells Workiva Shares
- Share Reduction Details: Readystate Asset Management LP disclosed a reduction of 361,224 shares in Workiva during Q4 2025, with an estimated transaction value of $31.98 million, reflecting a significant decline in confidence as the holding's value dropped by $31.09 million, indicating negative market sentiment towards Workiva.
- Ownership Percentage Shift: As of December 31, 2025, Readystate's stake in Workiva decreased to 0.03%, highlighting a substantial reduction in its significance within the asset management portfolio, which may affect investor attention towards the company.
- Market Performance Analysis: As of February 17, 2026, Workiva shares were priced at $58.00, down 35.4% year-over-year and underperforming the S&P 500 by 46.8 percentage points, indicating a lack of competitive strength in the market that could influence future investment decisions.
- Investor Outlook: Readystate nearly liquidated its entire position in Workiva in Q4 2025, retaining only 10,000 shares, suggesting a significant loss of confidence in the SaaS stock, which may impact Workiva's future financing capabilities and market positioning.
See More
Strong Dividend ETF Recommendation
- Dividend Yield: The Schwab U.S. Dividend Equity ETF (SCHD) recently offers a dividend yield of 3.3%, providing a stable income source amidst current economic uncertainties, appealing to defensive investors.
- Historical Performance: Since its inception in 2011, the ETF has achieved an average annual return of 13.30%, with a 15.67% return over the past year, demonstrating strong performance in volatile markets and boosting investor confidence.
- Portfolio Strength: SCHD holds approximately 100 stocks, including blue-chip companies like Lockheed Martin, Coca-Cola, and PepsiCo, ensuring investment diversity and stability, thereby providing long-term capital appreciation potential for investors.
- Long-Term Investment Returns: Investing $1,200 annually, with an assumed annual return of 10%, could yield around $68,730 after 20 years, highlighting the ETF's appeal as a long-term investment vehicle.
See More
Strong Performance of Health-Focused Dividend ETF
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
See More
Analysis of High-Yield Stocks in Pharma Sector
- Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
- Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
- Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
- Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
See More
Top High-Yield Healthcare Stocks to Consider
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
See More
Readystate Asset Management Significantly Reduces Workiva Holdings
- Significant Reduction: Readystate Asset Management sold 361,224 shares of Workiva in Q4 2025, with an estimated transaction value of $31.98 million, reflecting the fund's strategic response to market volatility.
- Decline in Position Value: The quarter-end value of Workiva holdings decreased by $31.09 million, indicating a dual impact from both stock price fluctuations and the share sale, suggesting a potential decline in market confidence towards the company.
- Change in Holdings Proportion: Post-sale, Readystate holds only 10,000 shares of Workiva valued at $862,500, which constitutes 0.03% of its AUM, thus removing Workiva from the fund's top five holdings, highlighting a significant shift in investment strategy.
- Uncertain Market Outlook: Although Workiva's price-to-sales ratio has fallen below 4, indicating potential valuation attractiveness, the impact of AI models on SaaS business models raises uncertainties about future investment returns, necessitating cautious evaluation by investors.
See More
Readystate Asset Management Sells Workiva Shares
- Share Reduction Details: Readystate Asset Management LP disclosed a reduction of 361,224 shares in Workiva during Q4 2025, with an estimated transaction value of $31.98 million, reflecting a significant decline in confidence as the holding's value dropped by $31.09 million, indicating negative market sentiment towards Workiva.
- Ownership Percentage Shift: As of December 31, 2025, Readystate's stake in Workiva decreased to 0.03%, highlighting a substantial reduction in its significance within the asset management portfolio, which may affect investor attention towards the company.
- Market Performance Analysis: As of February 17, 2026, Workiva shares were priced at $58.00, down 35.4% year-over-year and underperforming the S&P 500 by 46.8 percentage points, indicating a lack of competitive strength in the market that could influence future investment decisions.
- Investor Outlook: Readystate nearly liquidated its entire position in Workiva in Q4 2025, retaining only 10,000 shares, suggesting a significant loss of confidence in the SaaS stock, which may impact Workiva's future financing capabilities and market positioning.
See More
Strong Dividend ETF Recommendation
- Dividend Yield: The Schwab U.S. Dividend Equity ETF (SCHD) recently offers a dividend yield of 3.3%, providing a stable income source amidst current economic uncertainties, appealing to defensive investors.
- Historical Performance: Since its inception in 2011, the ETF has achieved an average annual return of 13.30%, with a 15.67% return over the past year, demonstrating strong performance in volatile markets and boosting investor confidence.
- Portfolio Strength: SCHD holds approximately 100 stocks, including blue-chip companies like Lockheed Martin, Coca-Cola, and PepsiCo, ensuring investment diversity and stability, thereby providing long-term capital appreciation potential for investors.
- Long-Term Investment Returns: Investing $1,200 annually, with an assumed annual return of 10%, could yield around $68,730 after 20 years, highlighting the ETF's appeal as a long-term investment vehicle.
See More
Strong Performance of Health-Focused Dividend ETF
- Annual Returns: The Schwab U.S. Dividend Equity ETF has achieved an average annual gain of 13.37% over the past decade, demonstrating robust performance in a volatile market, appealing to investors seeking stable returns.
- Dividend Yield: With a recent dividend yield of 3.3%, this ETF not only provides a steady cash flow but also offers the potential for capital appreciation, making it suitable for defensive investing in uncertain economic conditions.
- Investment Returns: Investing $1,200 annually with an assumed annual return of 10% could yield approximately $68,730 in 20 years, highlighting the power of compounding and encouraging a focus on long-term holding strategies.
- Portfolio Composition: The ETF holds around 100 stocks, primarily blue-chip companies, with top holdings like Lockheed Martin and Coca-Cola, further enhancing the stability and income potential of its investment portfolio.
See More
Analysis of High-Yield Stocks in Pharma Sector
- Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
- Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
- Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
- Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
See More
Top High-Yield Healthcare Stocks to Consider
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
See More
